GlassScriptPhysician profile
Anurag Agarwal
NPI 1962482836
$7,828.28
in general payments reported to CMS, 2019-2025
39 companies · $948 in 2025
The $948 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $278 · 2021: $4,602 · 2022: $861 · 2023: $240 · 2024: $623 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $2,932.71 | 2020-2025 | Optune, Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $1,839.33 | 2019-2021 | |
| Teleflex LLC | $360.55 | 2025 | Barrigel |
| Sirtex Medical INC | $350.57 | 2020-2023 | Sir-Spheres Microspheres |
| Janssen Biotech, INC. | $264.63 | 2021-2025 | Erleada, Akeega, Tecvayli |
| Novartis Pharmaceuticals Corporation | $263.22 | 2021-2023 | |
| Q Biomed INC. | $179.54 | 2020 | |
| Icotec Medical INC. | $153.64 | 2024 | Icotec Blackarmor Spine System |
| Argon Medical Devices, INC. | $150.95 | 2025 | Clot Management |
| Abbott Laboratories | $141.11 | 2019 | |
| Boston Scientific Corporation | $132.38 | 2025 | Spaceoar Vue System - 10ml |
| Cerapedics INC. | $112.61 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Astrazeneca Pharmaceuticals LP | $110.01 | 2019-2023 | |
| Brainlab, INC. | $97.00 | 2025 | Brainlab, INC. |
| Amgen INC. | $80.67 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.65 | 2021-2022 | |
| Eisai INC. | $51.53 | 2021-2022 | |
| Genzyme Corporation | $51.26 | 2021 | |
| Monteris Medical Corporation | $50.23 | 2022-2023 | Neuroblate |
| Ipsen Biopharmaceuticals, INC | $40.79 | 2022 | |
| Pfizer INC. | $40.46 | 2022 | |
| Myriad Genetic Laboratories, INC. | $34.46 | 2021 | |
| Progenics Pharmaceuticals, INC. | $30.99 | 2022 | |
| Fortovia Therapeutics, INC. | $24.78 | 2019 | |
| Reflexion Medical, INC. | $24.75 | 2025 | Reflexion Medical Radiotherapy System |
| Coherus Oncology, INC. | $23.79 | 2021 | |
| Adaptive Biotechnologies Corporation | $22.55 | 2022 | |
| Pharmacosmos Therapeutics INC. | $22.22 | 2022 | |
| Celgene Corporation | $21.88 | 2022 | |
| Lilly USA, LLC | $21.63 | 2022 | |
| Morphosys, US INC. | $21.63 | 2021 | |
| Incyte Corporation | $19.87 | 2021 | |
| Daiichi Sankyo INC. | $18.81 | 2020 | |
| Advanced Accelerator Applications | $17.62 | 2020 | |
| Mirati Therapeutics, INC. | $16.59 | 2023 | Krazati |
| Foundation Medicine, INC. | $14.13 | 2021 | |
| Seagen INC. | $13.91 | 2021 | |
| Merck Sharp & Dohme LLC | $12.76 | 2022 | |
| Elekta, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anurag Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.